Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Tamsulosin metabolism involves both CYP2D6 and 3A4. However, data on potential drug-drug interactions between tamsulosin and inhibitors of CYP2D6 and 3A4 are limited and information on potential pharmacodynamic consequences of such pharmacokinetic interactions is missing. WHAT THIS STUDY ADDS This study provides information on the drug-drug interactions of tamsulosin with strong CYP2D6 and strong CYP3A4 inhibitors after single dose administration in healthy subjects. AIM To determine the effect of the strong CYP2D6 inhibitor paroxetine and strong CYP3A4 inhibitor ketoconazole on the pharmacokinetics and safety (orthostatic challenge) of tamsulosin. METHODS Two open-label, randomized, two-way crossover studies were conducted in healthy male volunteers (extensive CYP2D6 metabolizers). RESULTS Co-administration of multiple oral doses of 20 mg paroxetine once daily with a single oral dose of the 0.4 mg tamsulosin HCl capsule increased the adjusted geometric mean (gMean) values of C(max) and AUC(0,∞) of tamsulosin by factors of 1.34 (90% CI 1.21, 1.49) and 1.64 (90% CI 1.44, 1.85), respectively, and increased the terminal half-life (t(1/2) ) of tamsulosin HCl from 11.4 h to 15.3 h. Co-administration of multiple oral doses of 400 mg ketoconazole once daily with a single oral dose of the 0.4 mg tamsulosin increased the gMean values of C(max) and AUC(0,∞) of tamsulosin by a factor of 2.20 (90% CI 1.96, 2.45) and 2.80 (90% CI 2.56, 3.07), respectively. The terminal half-life was slightly increased from 10.5 h to 11.8 h. These pharmacokinetic changes were not accompanied by clinically significant alterations of haemodynamic responses during orthostatic stress testing. CONCLUSION The exposure to tamsulosin is increased upon co-administration of strong CYP2D6 inhibitors and even more so of strong 3A4 inhibitors, but neither PK alteration was accompanied by clinically significant haemodynamic changes during orthostatic stress testing.

[1]  L. Lewis,et al.  Drug-drug interactions: is there an optimal way to study them? , 2010, British journal of clinical pharmacology.

[2]  S. Higuchi,et al.  Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. , 2010, British journal of clinical pharmacology.

[3]  J. Rosette,et al.  Pharmacokinetics and Pharmacodynamics of Tamsulosin in its Modified-Release and Oral Controlled Absorption System Formulations , 2010, Clinical pharmacokinetics.

[4]  M. Michel.  The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: alpha-blockers in the treatment of male voiding dysfunction - how do they work and why do they differ in tolerability? , 2010, Journal of pharmacological sciences.

[5]  Siep Thomas,et al.  Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. , 2009, The Journal of urology.

[6]  L. Signorello,et al.  Race and socioeconomic status are independently associated with benign prostatic hyperplasia. , 2008, The Journal of urology.

[7]  J. Nickel,et al.  A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia , 2008, International journal of clinical practice.

[8]  M. Miner,et al.  A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. , 2007, Clinical therapeutics.

[9]  R. Roberts,et al.  A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. , 2005, The Journal of urology.

[10]  M. Kähönen,et al.  The vasodilatory effect of alfuzosin and tamsulosin in passive orthostasis: a randomised, double-blind, placebo-controlled study. , 2005, European urology.

[11]  W. Krauwinkel,et al.  The Pharmacokinetic Profile of Tamsulosin Oral Controlled Absorption System (OCAS , 2005 .

[12]  W. Krauwinkel,et al.  Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation , 2005 .

[13]  W. Krauwinkel,et al.  Cardiovascular Safety of Tamsulosin Modified Release in the Fasted and Fed State in Elderly Healthy Subjects , 2005 .

[14]  D. Greenblatt,et al.  Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[15]  Jerome J. Schentag,et al.  Effect of Concomitant Administration of Cimetidine Hydrochloride on the Pharmacokinetic and Safety Profile of Tamsulosin Hydrochloride 0.4 mg in Healthy Subjects , 2002 .

[16]  M. Michel,et al.  A 6-month large-scale study into the safety of tamsulosin. , 2001, British journal of clinical pharmacology.

[17]  A. Tubaro.  A meta-analysis of the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction , 2000 .

[18]  R. Lefebvre,et al.  Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers , 2000, Clinical pharmacology and therapeutics.

[19]  M. Marberger,et al.  A Meta-Analysis on the Efficacy and Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction , 1999, European Urology.

[20]  A. Tewari,et al.  A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. , 1998, The Journal of urology.

[21]  T. Watanabe,et al.  Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[22]  H. Schumacher,et al.  Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? , 1998, The Journal of urology.

[23]  H. Lepor.  Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. , 1998, Urology.

[24]  T. Moreland,et al.  A Double-Blind Comparison of Terazosin and Tamsulosin on Their Differential Effects on Ambulatory Blood Pressure and Nocturnal Orthostatic Stress Testing , 1998, European Urology.

[25]  P. Abrams,et al.  A dose‐ranging study of the efficacy and safety of tamsulosin, the first prostate‐selective a1A‐adrenoceptor antagonist*, in patients with benign prostatic obstruction , 1997 .

[26]  S. Higuchi,et al.  Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling. , 1997, Journal of pharmaceutical sciences.

[27]  F. Lowe.  Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. , 1997, Clinical therapeutics.

[28]  M. Michel,et al.  Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. , 1997, The Journal of pharmacology and experimental therapeutics.

[29]  T. Watanabe,et al.  Absorption, metabolism and excretion of tamsulosin hydrochloride in man. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[30]  P. Abrams,et al.  Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. , 1996, European urology.

[31]  T. Mets.  Drug-Induced Orthostatic Hypotension in Older Patients , 1995, Drugs & aging.

[32]  P. Neuvonen,et al.  Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. , 1995, Clinical pharmacology and therapeutics.

[33]  P. Neuvonen,et al.  Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole , 1994, Clinical pharmacology and therapeutics.